What We're Reading: Page 182
Industry reads hand-picked by our editors
Sep 17, 2020
-
Reuters
Delaware judge deals Biogen another blow in Tecfidera patent fight
-
Bloomberg
HHS Steered $700 Million From CDC to Fund Warp Speed Program
-
MM&M
Behind ‘the apology’: Wayne Pines, who counseled FDA Commissioner Hahn to clarify plasma remarks, addresses the controversy
-
Endpoints News
Sarepta faces another gene therapy hiccup as Regenxbio sues over Jim Wilson's patent
Sep 16, 2020
-
Reuters
U.S. FDA's Hahn plans 'significant' work with AstraZeneca in COVID-19 trial inquiry
-
Bloomberg
Illumina Nears Deal to Buy Health-Care Startup Grail
-
Endpoints News
A month after losing its lead program, Unity Biotechnology cuts 30% of staff in restructuring
-
The Wall Street Journal
How Biotech Investors Can Survive Election Season
Sep 15, 2020
-
Kaiser Health News
NIH 'Very Concerned' About Serious Side Effect in Coronavirus Vaccine Trial
-
The Wall Street Journal
Kodak Deal Draws Review From Watchdog at Agency Involved in Planned Loan
-
Reuters
Marinus genetic epilepsy drug meets main goal of late-stage study
Sep 14, 2020
Sep 11, 2020
Sep 10, 2020
Sep 09, 2020
-
Reuters
How drugmakers can keep their pledge and still deliver an October vaccine surprise
-
The Wall Street Journal
Recursion Raises $239 Million Series D Round, Strikes Deal With Bayer
-
OneZero
The Next Gene-Edited Babies Could Be Free of Sickle Cell or Muscular Dystrophy
-
Evaluate Vantage
Big pharma spinouts grow up
Previous
